Immunotherapy and chemotherapy before surgery for early triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your breast cancer must be 'triple-negative' (ER-, PR-, HER2-).
- Your tumor must be larger than 2 cm.
- You must be in good general health (ECOG score 0-1).
- You must be willing to have surgery after the treatment period.
- If you can become pregnant, you must use effective birth control during and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.